Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.
Hills RK., Bradley R., Braybrooke J., Gray RG., Taylor H., Denkert C., Badve SS., Kim RS., Lacroix-Triki M., Regan MM., Hayes DF., Dowsett M., Tutt ANJ., Gelber RD., Cameron DA., Bergh JCS., Swain SM., Michiels S., Loi S., Salgado R.